Skyrizi, risankizumab-rzaa

About Skyrizi

Skyrizi (risankizumab-rzaa) is manufactured by AbbVie and was first approved by the US FDA in 2019 for moderate-to-severe plaque psoriasis in adults. The label has since expanded to include psoriatic arthritis, moderately-to-severely active Crohn's disease, and moderately-to-severely active ulcerative colitis. Skyrizi is a humanized immunoglobulin G1 monoclonal antibody that selectively targets the p19 subunit of interleukin twenty-three, a cytokine central to the inflammation behind these conditions.

Skyrizi is widely viewed as one of the most effective biologics for plaque psoriasis, with a high proportion of patients reaching clear or near-clear skin in trial settings. It also offers a relatively long dosing interval, which is part of why patients and physicians ask about it across borders. Reserve Meds coordinates US-sourced Skyrizi for international patients through a documented named-patient pathway with full DSCSA serial traceability.

How Skyrizi works

Skyrizi is an anti-IL-23 monoclonal antibody. Interleukin twenty-three is a signaling protein your immune system uses to coordinate inflammation, particularly in skin, joints, and the gastrointestinal tract. In psoriasis, psoriatic arthritis, and inflammatory bowel disease, IL-23 activity is elevated, and that elevation drives the visible disease: plaques on skin, swollen and painful joints, or ulcerated bowel. Risankizumab binds to the p19 subunit of IL-23 with high specificity, preventing IL-23 from engaging its receptor. The downstream inflammatory cascade quiets, and tissue can heal.

Because the antibody targets a single, specific cytokine subunit rather than broadly suppressing the immune system, the side-effect profile in trials has been favorable compared to older systemic therapies. Patients typically begin to see skin improvement within the first few weeks, with peak response generally achieved by week sixteen and maintained on the every-twelve-week schedule.

FDA indications

• Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
• Active psoriatic arthritis in adults.
• Moderately-to-severely active Crohn's disease in adults.
• Moderately-to-severely active ulcerative colitis in adults.

Dosing and route

For plaque psoriasis and psoriatic arthritis, Skyrizi is given as a 150 mg subcutaneous injection at week zero, week four, and then every twelve weeks after that. The maintenance dose of one injection every three months is one of the longest dosing intervals among IL-23 inhibitors.

For Crohn's disease and ulcerative colitis, treatment begins with a three-dose intravenous induction (600 mg at weeks zero, four, and eight) administered by a healthcare professional, followed by subcutaneous maintenance dosing of 180 mg or 360 mg every eight weeks. The induction regimen and maintenance dose are selected by the treating gastroenterologist based on disease severity and response.

Skyrizi is supplied as a single-dose pre-filled pen, pre-filled syringe, or on-body injector for subcutaneous administration, and as a single-dose vial for intravenous induction. Storage is refrigerated between thirty-six and forty-six degrees Fahrenheit. Reserve Meds ships every Skyrizi order under validated cold-chain conditions.

Common side effects

The most frequently reported side effects in trials include upper respiratory tract infections, headache, fatigue, injection-site reactions, tinea infections, and pruritus. Less common but more serious risks include serious infections (Skyrizi should not be started in patients with active infection), hypersensitivity reactions, and reactivation of latent tuberculosis. Tuberculosis screening is required before starting Skyrizi, and patients with latent tuberculosis should be treated before initiating therapy. Live vaccines should be avoided during treatment.

The risk of malignancy on IL-23 inhibitors appears to be low in available data, but long-term cohorts are still maturing. Patients should report new or unexplained symptoms to their treating physician promptly.

Cross-border named-patient access

Reserve Meds operates a named-patient program for Skyrizi. The pathway is built for international patients who have a valid prescription from a treating physician in their home country and want a US-sourced, DSCSA-traceable supply shipped to them on a documented regulatory pathway. We do not stock inventory, we do not ship without a prescription, and we do not operate inside the US prescription market. Every shipment is patient-specific, physician-authorized, and routed through a US specialty wholesaler with full serialization on every unit.

Reserve Meds does not replace the relationship with a treating physician. We coordinate the supply leg, the documentation leg, and the cold-chain leg. The clinical leg, including induction dosing, lab monitoring, and adverse event management, stays with the patient's dermatologist, rheumatologist, or gastroenterologist in the destination country.

How Reserve Meds coordinates Skyrizi

1. Patient or treating physician submits a named-patient request.
2. Clinical team verifies appropriateness of Skyrizi for the patient and destination country.
3. Treating physician issues prescription and clinical justification, including tuberculosis screening status.
4. Country-specific NPP or personal-import documentation is prepared.
5. Skyrizi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy under validated cold-chain conditions, with continuous temperature monitoring end to end.